last year 1st 4 months sales were $368m. so if we assume 30% growth then an acceptable number would be $470m or so.
Assume they maintain similar growth for the year we should see full year sales of $1.7b or about 3% higher than analysts forecasts. At $1.7 b they have added around $400m of sales and $225m of cash flow. or another way to look at it is they have added $150m of EBITDA (ex USA losses). BAL waa acquired at 30x EBITDA. $150m x 30x = $4.5m. in share value they are adding value around $6 per annum. ALLOF IT ENDS UP AS CASH ON BALBCE SHEET
EBITDA harder go guess as it depends on whether they have spent as much as they expected.
- Forums
- ASX - By Stock
- A2M
- 4m 1920FY estimate
4m 1920FY estimate, page-40
-
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add A2M (ASX) to my watchlist
(20min delay)
|
|||||
Last
$6.86 |
Change
-0.025(0.36%) |
Mkt cap ! $4.959B |
Open | High | Low | Value | Volume |
$6.93 | $6.98 | $6.83 | $5.625M | 812.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 206 | $6.85 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.86 | 9785 | 16 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 1531 | 6.850 |
23 | 23990 | 6.840 |
21 | 36948 | 6.830 |
17 | 37364 | 6.820 |
14 | 27616 | 6.810 |
Price($) | Vol. | No. |
---|---|---|
6.860 | 10447 | 17 |
6.870 | 27248 | 17 |
6.880 | 20716 | 15 |
6.890 | 25722 | 12 |
6.900 | 33084 | 14 |
Last trade - 13.57pm 15/07/2024 (20 minute delay) ? |
Featured News
A2M (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online